Introduction {#s1}
============

Microbial keratitis (MK) is a major cause of blindness worldwide, and affects an estimated 840,000 people per year in India alone (Whitcher et al., [@B49]). In severe corneal ulceration, despite adequate antimicrobial therapy, the disease can progress resulting in corneal perforation in up to 30% and loss of the eye in up to 25% of patients (Poole, [@B37]; Burton et al., [@B7]). The spectrum of organisms that cause MK varies geographically, with filamentous fungi (e.g., *Fusarium* sp. and *Aspergillus* sp.) accounting for up to 50% of all MK in tropical regions such as South India (Srinivasan et al., [@B42]). In more temperate climates, bacterial pathogens such as *Pseudomonas aeruginosa* and *Streptococcus pneumoniae* predominate, although there have been some notable outbreaks of filamentary fungal infections related to contact lens solutions in recent years (Tuft and Matheson, [@B47]; Galarreta et al., [@B13]; Gorscak et al., [@B15]).

Although some pathogens are able to produce enzymes that can damage the cornea, much of the corneal destruction in MK is likely due to an excessive host inflammatory response (Steuhl et al., [@B43]; Gopinathan et al., [@B14]). Several factors are thought to contribute to this tissue destruction and subsequent poor clinical outcome in MK. Tissue macrophages resident in the cornea detect pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs) such as Dectin-1 and toll-like receptors resulting in production of cytokines such as IL1B and chemokines (e.g., CXCL1, CXCL5) which result in a rapid influx of neutrophils (Leal et al., [@B26]; Sun et al., [@B44]). Activated neutrophils attempt to destroy the pathogen through production of reactive oxygen species and release of enzymes such as matrix metalloproteinases (MMPs) but these mechanisms can also damage surrounding host tissue. Additional sources of MMPs during MK include host corneal epithelial cells and activated keratocytes, causing an excess of these enzymes that can contribute to further tissue destruction, and even cornea perforation (Matsubara et al., [@B30]). By using a transcriptomic approach, Huang et al. investigated the entire murine corneal response to early *P. aeruginosa* infection and found increased gene expression for pro-inflammatory cytokines (e.g., *IL1B, TNF*), chemokines (e.g., *CXCL2*), in the corneas that developed perforation (Huang and Hazlett, [@B21]). Genes that protected against apoptosis, e.g., *BCL2*, were also upregulated in perforated corneas, implying prolonged survival of immune effector cells and therefore an extended inflammatory response (Huang and Hazlett, [@B21]).

Several studies have shown that host response to bacterial and fungal pathogens infecting the cornea appear to converge into common biological pathways as disease progresses (Karthikeyan et al., [@B23], [@B24]). However, there remains a paucity of data on the specific molecular mechanisms within these pathways in human MK. In order to better understand the immunopathogenesis of this disease, we have investigated the human corneal transcriptome in bacterial keratitis (BK) and fungal keratitis (FK) compared with the normal non-infected cadaveric cornea as the control (C), using Illumina HumanHT-12 v4 microarrays. We then validated our findings in a separate cohort of MK patients with an earlier stage of disease using real time quantitative reverse transcriptase PCR (RTqPCR).

Methods {#s2}
=======

This study was carried out in accordance with the recommendations of the Ethical Guidelines for Biomedical Research from The Indian Council of Medical Research. The protocol was approved by the Ethics Committees of the London School of Hygiene and Tropical Medicine (ref. no. 6118), Aravind Eye Care System (application no. IRB2011003CLI), and the Indian Council of Medical Research (ref. no. 53/2/oph/indo-foreign/12/NCDII). All subjects and relatives of the deceased (for inclusion of cadaver corneas) gave written informed consent in accordance with the Declaration of Helsinki.

Participant enrolment: microarray study
---------------------------------------

Adult subjects (aged ≥ 18 years) undergoing corneal transplantation at Aravind Eye Hospital (AEH) for culture-positive MK were enrolled into the study between January 2012 and 2013. Corneal scrapes were taken from the ulcer at presentation for microbiological culture. Sociodemographic data and ulcer clinical feature data were recorded into a standardized study form on the day of or day before surgery. Immediately after surgical excision, the corneal tissue was cut into four quadrants through the center of the ulcer using sterile technique. Two adjacent quadrants were placed into RNALater (Ambion, TX), stored at 4°C for 24 h, then −80°C until RNA extraction. The remaining two quadrants were formalin-fixed and paraffin wax embedded for an additional experiment. Thirteen adult cadaver corneas that were not eligible for corneal transplantation (due to inadequate endothelial cell count) and with no evidence of pathology on slit lamp examination were collected from Aravind Eye Bank between January 2012 and 2013 and preserved in RNAlater as described above.

Participant enrolment: validation cohort
----------------------------------------

Between March 2012 and February 2013, we recruited an independent series of consecutive patients as defined as all patients who presented daily to the cornea clinic at AEH with culture-positive BK or FK and with a moderate/large corneal ulcer (defined as stromal infiltrate ≥ 3 mm in longest diameter and extending \>1/3 into the corneal stroma as assessed by slit lamp biomicroscopy) who met the study inclusion/exclusion criteria. Sociodemographic/clinical data were recorded in the standardized study form. After application of a 0.5% proparacaine anesthetic eyedrop (Aurocaine, Aurolab, Madurai, India), a sterile Dacron swab (Puritan Medical, ME) was gently swept across the base and leading edge of the ulcer, then immediately placed into RNAlater. This was kept at 4°C for 24 h, then stored at −80°C until RNA extraction. Then a corneal scrape was taken from the ulcer base and leading edge and material transferred on to two glass slides and two sterile agar plates (blood and potato dextrose agar) for microbiological diagnosis.

Microbiological diagnosis
-------------------------

For microscopy, the slides stained with gram stain (for bacteria) and 10% potassium hydroxide (to aid in identification of fungal filaments) and examined by an experienced microbiologist. For culture, blood agar plates were incubated at 37°C for 2 days, and potato dextrose agar plates at 27°C for 1 week; agar plates were examined daily for any growth. A positive culture was defined as growth of the same organism on both solid media, or semi-confluent growth at the inoculation site in one solid medium matching the organism identified on microscopy; organisms grown were identified using methods described elsewhere (Wilhelmus et al., [@B50]). For fungal speciation, we used colony morphology and characteristic microscopic appearances of lactophenol cotton blue-stained hyphae and conidia, as described elsewhere (Thomas, [@B46]; Guarner and Brandt, [@B16]). Any culture and microscopy negative corneal ulcers were not included in the study.

RNA extraction
--------------

Total RNA was extracted from corneal tissue using TRIzol (Invitrogen, Carlsbad, CA) after tissue was ground in liquid nitrogen. RNA concentration was estimated by fluorescence (Qubit, Invitrogen). Any microarray samples with \<70 ng/μL of RNA underwent speed vacuum concentration (Eppendorf Concentrator Plus, Hamburg, Germany). RNA purity was assessed using Agilent Bioanalyzer RNA 6000 Nanochip (Agilent Technologies Inc., Palo Alto, CA) and samples with RNA integrity number values ≥7 and/or intact 18S and 28S RNA were selected for microarray. For corneal swabs from the validation cohort, total RNA was extracted using the RNeasy micro kit (Qiagen, Netherlands) and RNA quantity estimated using Nanodrop ND-1000 spectrophotometer (ThermoScientific, Waltham, MA).

Microarray experiment
---------------------

Total RNA (150 ng) from the 30 samples that passed RNA quality control (QC) measures described above underwent conversion to biotin labeled a-RNA (Target Amp Nano-g Biotin a-RNA labeling kit, EpiCenter Biotechnologies, Madison, WI) and was hybridized on to Illumina HumanHT-12 v4 beadchips (Illumina Inc., San Diego, CA) as per the manufacturer\'s protocol (Illumina, [@B22]). Disease and control samples were randomized between the three beadchips used. Fluorescence intensities were imaged with the BeadArray reader (Illumina Inc.). Each beadchip contained 47,231 probes covering the whole-genome and known splice variants. The definition of a probe in the Illumina HT-12 v4 beadchip is a 50-mer sequence-specific oligonucleotide that is designed to recognize a single gene with sequences originating from the National Center for Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 (November 7, 2009) and legacy UniGene content (Illumina, [@B22]).

The microarray raw and normalized data are available at NCBI Gene Expression Omnibus repository under accession number [GSE58291](GSE58291). QC checks for sample-independent and sample-dependent controls were performed in GenomeStudio version 3.1 (Illumina Inc.) and data exported to Lumi in Bioconductor in R for analysis (Du et al., [@B9]). Pairwise comparisons were defined as BK or FK vs. controls, and BK vs. FK. Probe-level raw data were divided into subsets according to these pairwise comparisons and only samples involved in a given comparison were included in that analysis. Data were filtered to remove non-expressed probes (probes whose fluorescence was not statistically significantly different to negative control probes, i.e., *p* \> 0.01). Variance stabilizing transformation followed by quantile normalization were applied to reduce variation due to non-biological differences (Lin et al., [@B29]). Prior to normalization, samples were ordered by strength of their pairwise correlations using agglomerative hierarchical clustering with complete linkage to identify outliers, and also principal component analysis was used with data from all samples to again identify outlying samples. Fold change (FC) was calculated as the antilog~2~ of the difference between the mean normalized expression intensity for each gene in each group in the pairwise comparison.

RTqPCR experiment
-----------------

RTqPCR was used to validate the microarray findings using RNA from a) the same microarray samples (except 1 sample with inadequate RNA remaining, M20 in FK) and b) samples from the validation cohort. For the RTqPCR, 48 genes were chosen from the most differentially expressed genes in the microarray using a literature search method to identify genes associated with the host response to bacterial/fungal infection or MK, and also included three genes (*IFNG, IL12B, IL17A*) that were not among the microarray differentially expressed genes (DEGs) but were considered to be of potential biological importance in MK. Three housekeeping genes (*GAPDH, HPRT1, RPP30*) were also included. Primers were selected from Taqman (Life Technologies, New York, USA) gene expression assays (Table [S1](#SM3){ref-type="supplementary-material"}) and pre-loaded into custom Taqman Low Density Array (TLDA) cards (Life Technologies) with eight samples per card. Technical replicates were run for eight randomly selected samples from the validation cohort and all microarray samples. Total RNA (100 ng) from each sample was converted to cDNA (Takara PrimeScript 1st strand cDNA synthesis kit, Takara Bio, Otsu, Shiga, Japan) in a 20 μL reaction volume; for samples with total RNA \<100 ng (*n* = 25), all sample RNA was used. TaqMan (Life Technologies) gene expression mastermix (50 μL), and cDNA were made up to 100 μL with RNAse-free water and loaded into TLDA cards, with disease and control samples randomized to be present on each card. RTqPCR was performed in the ABI 7900HT PCR thermal cycler (Life Technologies). Thermal cycling conditions were 50°C for 2 min; 94.5°C for 10 min (denaturation); 40 cycles of 97°C for 30 s then 59.7°C for 1 min (for annealing and extension). Raw cycle threshold (C~T~) data were collected in SDS RQ manager (Life Technologies) with baseline automatically detected. For samples run in duplicate, the arithmetic mean of C~T~ values was used in data analysis. C~T~ values were normalized to GAPDH as this housekeeping gene showed the best expression profile for all samples. Samples were considered to have failed gene expression if GAPDH was not expressed (i.e., C~*T*~ = 40) and median C~T~ for all 48 genes was \> 37, and were excluded from downstream analysis. FC was calculated as the mean normalized expression between groups, using 2^−(ΔCT(meangroup1)−ΔCT(meangroup2))^.

Statistical analysis
--------------------

Wilcoxon rank-sum test was used to compare clinical data in each group in Stata v12.1 (StataCorp, Texas, USA). Microarray and RTqPCR pairwise comparisons were assessed for statistical significance using empirical Bayes moderated *t*-tests (Limma package in Bioconductor in R) (Smyth, [@B41]). *P*-values were adjusted for multiple comparisons using the Benjamini-Hochberg false-discovery rate (FDR) (Benjamini and Hochberg, [@B3]).

Differential expression analysis
--------------------------------

Differentially expressed genes were defined as FDR-adjusted *p*-value \< 0.05 and FC ≥ 4 for upregulation or FC \< −4 for downregulation. For genes with multiple probes, the probe with the greatest absolute value of the FC was selected to represent the gene for all downstream analysis. FCs from microarray and RTqPCR were evaluated with Spearman\'s rank correlation since data were not normally distributed, as confirmed by the Shapiro-Wilk test (Stata v12.1, StataCorp). Genes that were non-expressed in the microarray were not included in the correlation calculations: *IL17A* and *IL12B* for all comparisons, and *IFNG* for FK vs. C. The list of differentially expressed genes was analyzed for gene ontology (GO) terms using Database for Annotation, Visualization, and Integrated Discovery (DAVID) v6.8 (Huang et al., [@B20]).

Protein-protein interaction (PPI) network analysis
--------------------------------------------------

A human PPI network was constructed using the HIPPIE v2.0 database (Schaefer et al., [@B40]) and visualized with Cytoscape version 3.4.0 (<http://www.cytoscape.org>) for differentially expressed genes unique to BK or FK as well as those genes common to both infections. The Molecular Complex Detection (MCODE) plugin was used within Cytoscape to assess highly interconnected clusters of proteins using default parameters (Degree Cutoff: 2, Node Score Cutoff: 0.2, K-Core: 2) (Bader and Hogue, [@B2]). Degree was defined as the number of connections that each gene had, and degree cutoff was defined the minimum number of connections allowed for each gene to be included in the network (Bader and Hogue, [@B2]).

Network analysis: Miru
----------------------

Normalized expression intensities for each gene expressed in the BK, FK, and C samples in the microarray experiment (*n* = 24,418 probes) were used to generate a Pearson correlation matrix in Miru (Theocharidis et al., [@B45]). As described above, for genes with multiple probes, the probe with the greatest absolute value of the FC was selected to represent the gene for the network analysis. The three samples found to be outliers in hierarchical clustering were excluded. A network graph was created with each gene drawn as a "node." The line drawn between two highly correlated nodes (i.e., correlation coefficient ≥ 0.9) is known as an "edge." The Markov Cluster Algorithm (MCL) was used to highlight natural clusters of the most highly correlated nodes, using standard settings in Miru and smallest cluster size of four nodes (Enright et al., [@B11]). Gene lists from each cluster were explored for GO term enrichment using DAVID v6.8.

Results {#s3}
=======

Socio-demographic features and microbiology
-------------------------------------------

For the microarray study, a total of 47 participants were enrolled (*n* = 19 controls, *n* = 10 BK, *n* = 18 FK). Corneal tissue from 16 of these participants failed initial RNA QC measures (*n* = 6 controls; *n* = 2 BK: 1 *S. pneumoniae* and 1 *P. aeruginosa*; *n* = 9 FK: 8 *Aspergillus* sp. and 1 *Fusarium* sp). Corneal tissue from the remaining 30 participants passed QC and underwent microarray analysis (*n* = 13 C, *n* = 9 FK, *n* = 8 BK). Hierarchical clustering revealed three outlier specimens that were excluded from further analyses (*n* = 1 BK, *n* = 1 FK, *n* = 1 C). For the validation cohort with earlier stage of disease, 205 participants were enrolled (*n* = 185 FK and 20 BK); 22 of these samples failed RTqPCR QC (*n* = 20 FK, *n* = 2 BK) and were excluded.

Table [1](#T1){ref-type="table"} summarizes socio-demographic and clinical features of the final 183 validation cohort and 27 microarray cohort participants. The control group had an older median age (*p* ≤ 0.001) compared to the other microarray participants, since most cadaver corneas were from deceased older subjects. In the microarray cohort, the symptom duration, ulcer size and visual acuity at presentation was similar in both bacterial and fungal ulcers (Table [1](#T1){ref-type="table"}; full details Table [S2](#SM4){ref-type="supplementary-material"}). All bacterial ulcers in the microarray cohort had corneal perforation, compared to only three in the fungal group; this reflects the different indications for performing corneal transplantation in these two groups. The validation cohort had less severe disease compared with participants in the microarray study, as evidenced by significantly better visual acuity and smaller ulcer size at presentation as well as fewer corneal perforations (Table [1](#T1){ref-type="table"}).

###### 

**Summary of clinical and sociodemographic data of study participants**.

                                                                                  **Controls (*n* = 12)**   **Bacterial keratitis (BK)**   **Fungal keratitis (FK)**   **BK vs. FK**                                                       
  ------------------------------------------------------------------------------- ------------------------- ------------------------------ --------------------------- --------------- ----------------- ----------------- -------- ------ ------
  Gender, No. Male (%)                                                            7 (58%)                   7 (100%)                       13 (72%)                    0.12            4 (50%)           105 (64%)         0.44     0.03   0.47
  Age, median (IQR), years                                                        82 (76.5--90)             67 (60--75)                    55 (35--62)                 0.02            52.5 (43--62.5)   50 (36.5--58)     0.44     0.04   0.41
  Symptom duration, median (range), days                                          --                        15 (7--20)                     10 (2--90)                  0.19            14.5 (2--43)      7 (1--90)         0.12     1.00   0.12
  Uncorrected visual acuity[^\*^](#TN1){ref-type="table-fn"}, median (IQR)        --                        1.9 (1.8--1.9)                 1.7 (1.7--1.8)              0.01            1.85 (1.8--1.9)   1.8 (0.56--1.8)   \<0.01   0.62   0.86
  Median stromal infiltrate size[^\*\*^](#TN2){ref-type="table-fn"} (mm), (IQR)   --                        7.0 (5.7--8.5)                 3.8 (3.2--5.1)              \<0.01          5.8 (4.3--9.2)    4.4 (3.5---5.5)   0.04     0.68   0.58
  Perforation                                                                     --                        7 (100%)                       1 (5%)                      0.01            3 (38%)           19 (11%)          \<0.01   0.01   0.44

*Visual Acuity measured in logMAR units:\>1.0, unable to read any letters on chart; 1.8, able to count fingers only; 1.9, able to see hand movements only; 2.0, perception of light only*.

*Stromal infiltrate size calculated as geometric mean of longest stromal infiltrate diameter and its perpendicular measurement (mm)*.

*All p-values generated by comparing microarray study participants vs. validation cohort, within bacterial or fungal keratitis groups*.

For the microarray study, bacterial ulcers were positive for *S. pneumoniae* (*n* = 6) and *P. aeruginosa* (*n* = 1), and fungal ulcers grew *Fusarium* sp. (*n* = 5), *Aspergillus flavus* (*n* = 1), *Aspergillus terreus* (*n* = 1), and *Lasiodiplodia* sp. (*n* = 1). In the validation cohort, most ulcers were fungal (*n* = 165) rather than bacterial (*n* = 23). The commonest fungi were *Fusarium* sp. (*n* = 69) and *A. flavus* (*n* = 25) and among the bacterial ulcers, the most frequent organism was *S. pneumoniae* (*n* = 8; Table [2](#T2){ref-type="table"}).

###### 

**Microbiological results of corneal ulcers**.

                                     **Microarray participants**   **Validation cohort**
  ---------------------------------- ----------------------------- -----------------------
  **BACTERIA**                                                     
  *Streptococcus pneumoniae*         6 (40%)                       8 (4.4%)
  *Pseudomonas aeruginosa*           1 (6.7%)                      3 (1.6%)
  *Nocardia* sp.                     --                            3 (1.6%)
  *Streptococcus viridans*           --                            2 (1.1%)
  *Aeromonas* sp.                    --                            1 (0.5%)
  *Staphylococcus epidermidis*       --                            1 (0.5%)
  **FUNGI**                                                        
  *Fusarium* sp.                     5 (33.3%)                     69 (37.7%)
  *Aspergillus flavus*               1 (6.7%)                      25 (13.7%)
  *Aspergillus terreus*              1 (6.7%)                      2 (1.1%)
  *Aspergillus fumigatus*            --                            4 (2.2%)
  *Lasiodiplodia* sp.                1 (6.7%)                      2 (1.1%)
  *Curvularia* sp.                   --                            5 (2.7%)
  *Exserohilum* sp.                  --                            5 (2.7%)
  *Alternaria* sp.                   --                            1 (0.5%)
  *Bipolaris* sp.                    --                            1 (0.5%)
  *Cylindrocarpon* sp.               --                            1 (0.5%)
  Unidentified dematiaceous fungus   --                            9 (4.9%)
  Unidentified hyaline fungus        --                            13 (7.1%)
  Microscopy positive (no growth)    --                            28 (15.3%)

Microarray study: global gene expression profile and differential expression analysis
-------------------------------------------------------------------------------------

Many genes (\>17,000) were found to be expressed in the BK and FK vs. C comparisons (Table [3](#T3){ref-type="table"}). Hierarchical clustering of transcriptome data revealed a clear difference in infected vs. control samples by their global gene expression profile using differentially expressed genes only (Figure [1](#F1){ref-type="fig"}), but there was no clear distinction between bacterial and fungal samples. Principal components analysis using whole-genome level expression also shows that control samples cluster together, but bacterial and fungal keratitis samples are interspersed (Figure [S1](#SM1){ref-type="supplementary-material"}). Differential expression analysis revealed a large number of genes to be differentially expressed in both bacterial and fungal ulcers compared to control tissue (shown in Table [S3](#SM5){ref-type="supplementary-material"}).

###### 

**Summary of expressed genes in microarray pairwise comparisons (FK, Fungal Keratitis; BK, Bacterial Keratitis; C, Controls)**.

                                                                           **FK vs. C**   **BK vs. C**   **BK vs. FK**
  ------------------------------------------------------------------------ -------------- -------------- ---------------
  No. of expressed genes                                                   17,753         17,434         17,120
  *p* \< 0.05                                                              6,414          7,825          18
  *p* \< 0.01                                                              4,119          5,384          0
  No. of differentially expressed genes[^\*^](#TN3){ref-type="table-fn"}   389            524            0
  Up-regulated                                                             291            361            0
  Down-regulated                                                           98             163            0

*Genes were considered differentially expressed if FDR-adjusted p-value \< 0.05 and fold change was \< --4 or ≥4*.

![**Plot of hierarchical clustering of log~2~ fold changes of differentially expressed genes from the final bacterial keratitis, fungal keratitis, and control samples used in the microarray experiment (*n* = 27)**. (Color scale red = log~2~FC of 8, green log~2~FC of 14). Bacterial and fungal ulcer samples are interspersed, but normal control tissue samples cluster together in the hierarchical cluster plot of the differentially expressed genes only. The whole-genome level expression profile of raw data for all samples is shown in Figure [S1](#SM1){ref-type="supplementary-material"}.](fcimb-07-00193-g0001){#F1}

Differentially expressed genes common to bacterial and fungal keratitis
-----------------------------------------------------------------------

Many of the differentially expressed genes were common to both BK and FK (*n* = 339; 250 upregulated and 89 downregulated; Table [S4](#SM6){ref-type="supplementary-material"}). Using this gene list with DAVID, the most significant GO terms enriched within the biological process category were: the inflammatory response, the immune response, and neutrophil chemotaxis (Table [4](#T4){ref-type="table"}), however there is a high degree of overlap of the genes that are present in these three GO terms (i.e., high redundancy). Additional GO terms that were significantly enriched are also shown in Table [S4](#SM6){ref-type="supplementary-material"}, and include regulation of the immune response, cytokine response, phagocytosis and cell-cell adhesion terms. Within the immune response term, the most highly upregulated cytokine genes included *IL1B* (along with its activator, the inflammasome *NLRP3*), Oncostatin M (*OSM*) and *TNF*, all of which had higher fold changes in bacterial ulcers. Many chemokine genes were upregulated (*CCL2, CCL3, CCL3L1, CCL4L1, CCL5, CCL7, CCL8, CCL13, CCL20*; *CXCL5, CXCL6*) and were found in the significantly enriched chemokine signaling pathway, chemokine activity, or chemokine receptor activity terms. Multiple GO terms associated with leukocyte chemotaxis were enriched and included upregulated genes promoting cell adhesion (e.g., the integrins *ITGB2, ITGAM, ITGAX*) or cell migration via actin filament organization (*HCK, FGR*), or pseudopodia formation (*AQP9*). PRR genes were also upregulated: *CD209 (DCSIGN), TLR2* (and its synergists *NOD2* and *MARCO*), *TLR4* (and co-receptor *CD14*), *TLR8*, as well as *SYK*, a TLR downstream signaling molecule. Elements of the adaptive immune system were also among the differentially expressed genes. The gene coding for the IL7 receptor (*IL7R*) present on naïve and memory T-cells, was strongly upregulated especially in BK. There was also indirect evidence of Th17 activity with high expression of genes coding for the Th17-chemokine *CCL2*. IFN-gamma activity may have been occurring since we observed increased gene expression for IFNG-induced genes (*IFI30, ISG15*). Serglycin, *SRGN*, the main component of cytotoxic T-cell, and NK cell dense granules also had upregulated gene expression.

###### 

**Top three most significantly enriched biological process Gene Ontology (GO) terms for microarray pairwise comparisons**.

                                                                                   **GO terms**                                         **Fold enrichment**   ***P*-value**
  -------------------------------------------------------------------------------- ---------------------------------------------------- --------------------- ---------------
  Genes common to both bacterial and fungal keratitis compared to control tissue   GO:0006955: immune response                          4.6                   5.37 E-50
                                                                                   GO:0006952: defense response                         4.3                   2.38 E -42
                                                                                   GO:0002682: regulation of immune system process      4.4                   9.68 E-19
  Genes unique to bacterial keratitis                                              GO:0006954: inflammatory response                    6.3                   3.63 E-13
                                                                                   GO: 0002682: regulation of immune system process     5.3                   6.89 E-13
                                                                                   GO:0001816: cytokine production                      8.7                   1.82 E-12
  Genes unique to fungal keratitis                                                 GO:1901700: response to oxygen-containing compound   4.3                   2.9 E-06
                                                                                   GO:0000302: response to reactive oxygen species      11.9                  1.2 E-04
                                                                                   GO:0009605: response to external stimulus            3.0                   1.5 E-04

*Analyses performed in DAVID v6.8 (all p-values unadjusted)*.

The defense response term was also found to be a significantly enriched biological processed. Genes that were expressed with high fold changes within this pathway included those in the complement system (*C1QC*; the receptor *C3AR*; complement activators *Ficolin 1, FCN1*, and FC-gamma receptors). However, the complement regulator gene, *Complement Factor H* (*CFH*), was downregulated. Genes involved in multiple microbial killing mechanisms were upregulated including those encoding antimicrobial peptides (*LYZ, DEFB4*), NADPH oxidase subunits (*NCF2, NCF4, CYBB, RAC2*), and phagolysosome components (late-endosome associated *SLC11A1*). Genes promoting ROS detoxification (*SOD2, CD53, IFI30*) and regulating excess ROS production were also upregulated (*EFHD1*).

Enriched cellular component GO terms included the extracellular space, region or exosome, the extracellular matrix (ECM) and the cell surface. Many MMP genes were found within these terms (i.e., *MMP1, MMP7, MMP9, MMP10, MMP12*), especially *MMP9*, which had the highest FC in both BK and FK (91 FC in BK, adj *p* = 3.64 E-12; 64 FC in FK, adj. *p* = 6.10 E-11). With regards to the corneal epithelium, we observed upregulation of genes from the epithelial differentiation complex such as keratins unique to the wound-healing phenotype (*KRT6B, KRT16*), and antimicrobial peptides (*PI3, S100A7, S100A8, S100A9*). Genes promoting stability of the epithelium such as *ASIP*, (associated with epithelial cell adhesion) and some corneal epithelial keratins (*KRT3, KRT12*) were all downregulated. For the corneal stroma, the gene for type 3 collagen, associated with wound healing, was also upregulated (*COL3A1*). However, keratocyte gene markers were downregulated, e.g., the main stromal proteoglycan keratocan (*KERA*), its sulphation enzyme *CHST6*, and the corneal crystallins (*ALDH1A1, ALDH3A1*). The myofibroblast gene marker alpha smooth muscle actin was not a month the differentially expressed genes in BK or FK, and the receptor that promotes myofibroblast differentiation (*TGFBR3*) was downregulated.

Differentially expressed genes unique to BK
-------------------------------------------

There were 185 uniquely differentially expressed genes in the BK samples (*n* = 111 upregulated, *n* = 74 downregulated). GO analysis identified the three most significant main biological processes to be the inflammatory response, regulation of the immune system, and cytokine production, which again contain many genes that overlap among all three GO terms (Table [4)](#SM6){ref-type="supplementary-material"}.

The neutrophil chemoattractant *CXCL2* was the most highly upregulated chemokine gene in the BK samples. Other pro-inflammatory genes that had increased expression included cytokines/cytokine receptors (i.e., *IL1A, IL1R2, IL6, IL18RAP*). Also, the gene for the PRR, *TLR4*, was upregulated.

*HIF1A* was one of the most highly upregulated genes in BK that was also a transcription factor. We also detected upregulation of multiple *HIF1A*-induced genes and these were involved in cellular processes such as mitochondrial fusion (*GNG2*).

Further GO analysis of the differentially expressed genes revealed that the main molecular function was receptor binding and cytokine activity. The main cellular component containing most of the differentially expressed genes according to GO analysis was the extracellular region. Examples of genes found within this category were claudin 5 (*CLDN5*) the endothelial cell tight junction, fibulin 2 *FBLN2*, that contributes to corneal elasticity and also a Descemet\'s membrane (DM) collagen (*COL8A1, COL8A2*); all of these genes were downregulated in the BK samples.

Differentially expressed genes unique to FK
-------------------------------------------

Fewer genes were differentially expressed uniquely in FK (*n* = 50; 41 upregulated and 9 downregulated). GO analysis highlighted the main biological processes to be response to reactive oxygen species or oxygen-containing compounds (Table [4](#T4){ref-type="table"}). The response to external stimulus GO term was also found to be significant in the FK samples, and included selected chemokines (e.g., *CCL22, CXCL10, CXCL13*) that were all upregulated. In addition, other biological process GO terms that were enriched included keratinization and epithelial cell differentiation (Table [S4](#SM6){ref-type="supplementary-material"}), that contained genes known to promote corneal re-epithelialization such as the cornified envelope proteins (*SPRR2A, SPRR2D, SPRR2F*, and *SPRR3*; Suprabasin, *SBSN*), which were all upregulated. Genes involved in epithelial adhesion such as the tight junction component desmoglein 1 (*DSG1*) were downregulated.

The GO terms enriched in the molecular function category were mainly associated with antioxidant activity, oxidoreductase activity or peroxidase activity, such as glutathione peroxidase 2 (GPX2) and the hemoglobin subunit genes *HBA2* and *HBB* that were upregulated in FK and present in many of these GO terms.

The cellular component GO terms that were enriched for FK were predominantly extracellular and included the cornified envelope, extracellular vesicle/exosome and the extracellular matrix (Table [S4](#SM6){ref-type="supplementary-material"}). Many genes overlapped between these GO terms, including the corneal collagens (*COL1A1, COL5A1*), a corneal crystallin (*ALDH3A2*), and an integrin (*ITGB7*).

Microarray probes differentially expressed between bacterial and fungal keratitis
---------------------------------------------------------------------------------

No genes were differentially expressed in the BK vs. FK comparison. The most upregulated gene was *SMPDL3A*, a nucleotide phosphodiesterase present in macrophages, with a fold change of 2.27 (fdr-adjusted *p* = 0.048) in BK samples compared to FK. The most downregulated gene was *ACVRL1*, a receptor in the TGF-beta signaling pathway, that had a fold change of 0.41 in BK vs. FK (fdr-adjusted *p* = 0.014; Table [S3](#SM5){ref-type="supplementary-material"}).

Network analysis: MCODE protein-protein interaction and network co-expression
-----------------------------------------------------------------------------

The protein-protein interaction network of all BK DEGs identified the most inter-connected genes as those involved in actin filament reorganization (*BTK, FGR, HCK, LYN, PLCG2, KIT*; see Figure [S2](#SM2){ref-type="supplementary-material"}). The remaining five clusters detected mainly genes involved in the immune response: chemokines (*CCL22, CCL5, CCR1, CXCR4, CXCL8*), TLR4 signaling (*TLR4, NOD2, IRAK2, IRAK3, RIPK2*), macrophage activity (*CCL7, CCL2, MMP1*), the cytokine *IL1B*, and the final cluster contained the transcription factor *BATF* (promotes Th17 differentiation) and *HLF* (protects against oxidative stress). For FK, MCODE identified only a single cluster which included the same chemokines as detected in BK (*CCL22, CCL5, CCR1, CXCR4, CXCL8*; shown in Figure [S2](#SM2){ref-type="supplementary-material"}).

Using all of the DEGs for BK and FK, a network co-expression graph was generated in Miru which consisted of 513 nodes and 18,592 edges. The most highly connected genes formed 7 clusters (found using Markov chain clustering algorithm - see Figure [S2](#SM2){ref-type="supplementary-material"}). Exploration of GO enrichment for each cluster (detailed in Table [S5](#SM7){ref-type="supplementary-material"}) showed several associated with the immune response, in particular leucocyte migration (cluster 1), cytokine production (cluster 1), or cytokine-mediated signaling pathway involvement (cluster 4) and regulation of T-cell activation (cluster 7). Other GO terms enriched in the remaining clusters included wound healing terms (blood vessel morphogenesis in cluster 2; lymphoid progenitor cell and epithelial cell differentiation in cluster 3; cytoskeleton organization in cluster 5) as well as protein folding associated with cytoplasmic vesicles (cluster 5).

Validation of microarray results using RTqPCR
---------------------------------------------

Comparison of the RTqPCR results for BK and FK vs. control, and vs. each other, for the microarray cohort and the validation cohorts are shown in Tables [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"} respectively. For RNA extracted from corneal tissue used in both the microarray and RTqPCR experiments, we found a high correlation between expression values for the genes tested (Spearman\'s rho 0.90 for BK and 0.90 for FK samples, *p* \< 0.0001 for both; Figure [2](#F2){ref-type="fig"}). We also found a high correlation for FK (Spearman\'s rho 0.74, *p* \< 0.0001) and moderate correlation for BK (Spearman\'s rho 0.66, *p* \< 0.0001) when comparing the gene expression of the corneal tissue used in the microarray experiment with that of corneal ulcers with late stage disease in the validation cohort of patients (symptom duration \> 7 days; *n* = 12 for BK, *n* = 71 for FK). When comparing early stage disease in the validation cohort (symptom duration ≤ 7 days; *n* = 5 for BK, *n* = 94 for FK) with corneal tissue in the microarray samples, we found the top three genes with the highest fold changes were *IL12B, IL23A* and *IL18* in BK, and *IL17A, IL23A* and *IFNG* in FK (Table [S6](#SM8){ref-type="supplementary-material"}). Within the validation cohort, there were no differentially expressed genes when comparing early vs. late stage disease or BK with FK samples.

###### 

**RTqPCR differential expression analysis results using RNA from microarray study participants**.

  **Category**              **Gene**     **BK vs. C**   **FK vs. C**   **BK vs. FK**                     
  ------------------------- ------------ -------------- -------------- --------------- ---------- ------ ----------
  Immune response           *CXCL5*      5284.76        1.15E-08       1458.86         2.97E-07   3.62   9.32E-01
                            *CXCL6*      209.81         3.41E-07       151.09          1.34E-06   1.39   9.32E-01
                            *CCL20*      93.32          3.32E-04       41.04           2.43E-03   2.27   9.32E-01
                            *CCL3L1*     26.57          3.82E-03       118.69          1.09E-04   0.22   9.32E-01
                            *CXCL1*      22.06          1.02E-03       8.86            1.48E-02   2.49   9.32E-01
                            *CXCL8*      624.37         1.22E-05       191.25          1.54E-04   3.26   9.32E-01
                            *IL1B*       240.14         3.22E-05       118.04          1.59E-04   2.03   9.32E-01
                            *TNF*        17.36          4.82E-04       9.80            3.96E-03   1.77   9.32E-01
                            *IL17A*      8.20           2.36E-02       1.30            7.82E-01   6.33   9.32E-01
                            *IL23A*      7.17           3.88E-02       9.48            1.87E-02   0.76   9.32E-01
                            *IFNG*       2.01           4.46E-01       1.18            8.47E-01   1.70   9.32E-01
                            *IL18*       0.93           9.05E-01       0.76            6.80E-01   1.23   9.32E-01
                            *IL12B*      0.55           4.77E-01       3.20            1.72E-01   0.17   9.32E-01
                            *TREM1*      136.48         2.77E-06       130.90          3.07E-06   1.04   9.95E-01
                            *CYTL1*      0.00           1.15E-08       0.02            1.54E-05   0.10   4.60E-01
                            *AQP9*       904.84         3.88E-08       259.07          1.34E-06   3.49   9.32E-01
  PRRs                      *CLEC4A*     79.40          8.36E-08       66.52           2.97E-07   1.19   9.32E-01
                            *CLEC7A*     1.83           3.36E-01       2.19            2.09E-01   0.84   9.32E-01
                            *FCER1G*     49.67          1.66E-06       54.44           1.34E-06   0.91   9.76E-01
                            *FCN1*       334.06         2.99E-08       271.71          1.32E-07   1.23   9.32E-01
                            *FPR1*       17.83          2.03E-04       13.38           6.31E-04   1.33   9.32E-01
                            *SCARA3*     0.09           2.33E-03       0.12            6.26E-03   0.76   9.32E-01
                            *TLR2*       9.11           1.64E-03       9.06            1.80E-03   1.00   9.95E-01
                            *TLR4*       27.73          9.41E-05       9.84            3.96E-03   2.82   9.32E-01
                            *MARCO*      159.96         2.73E-07       163.95          3.95E-07   0.98   9.95E-01
                            *NLRP3*      37.29          6.68E-05       19.28           6.17E-04   1.93   9.32E-01
  ECM                       *COL1A1*     4.91           9.18E-02       16.45           4.84E-03   0.30   9.32E-01
                            *COL5A1*     10.64          2.06E-02       19.80           4.36E-03   0.54   9.32E-01
                            *KERA*       0.00           2.26E-05       0.01            1.52E-04   0.44   9.32E-01
                            *KRT6B*      29.45          3.59E-03       94.62           2.15E-04   0.31   9.32E-01
                            *ALDH1A1*    0.04           6.68E-05       0.04            4.97E-05   1.09   9.76E-01
  MMPs                      *MMP1*       93.57          2.77E-06       110.98          1.70E-06   0.84   9.45E-01
                            *MMP10*      21.66          4.82E-04       10.67           4.90E-03   2.03   9.32E-01
                            *MMP12*      59.43          1.33E-04       110.09          2.58E-05   0.54   9.32E-01
                            *MMP28*      0.22           6.19E-02       0.33            1.68E-01   0.68   9.32E-01
                            *MMP7*       41.29          1.78E-04       51.95           9.64E-05   0.79   9.32E-01
                            *MMP9*       2117.89        7.16E-10       4151.54         8.34E-11   0.51   9.32E-01
                            *ADAM19*     34.91          4.58E-05       70.56           3.18E-06   0.49   9.32E-01
  Anti-microbial peptides   *PI3*        3551.44        9.58E-08       2181.29         3.95E-07   1.63   9.32E-01
                            *S100A7*     127.46         5.71E-04       427.84          4.97E-05   0.30   9.32E-01
                            *S100A9*     37.40          1.20E-04       60.60           2.58E-05   0.62   9.32E-01
                            *DEFB4B*     45.05          1.92E-03       84.92           4.65E-04   0.53   9.32E-01
  Peptidase inhibitors      *SERPINA1*   38.90          5.38E-06       46.80           2.67E-06   0.83   9.32E-01
                            *TIMP1*      3.98           5.34E-02       6.61            9.83E-03   0.60   9.32E-01
                            *TIMP3*      0.11           3.66E-03       0.29            8.72E-02   0.39   9.32E-01

*BK, Bacterial Keratitis; FK, Fungal keratitis; C, Controls; PRRs, Pattern Recognition Receptors; ECM, Extra-Cellular Matrix; MMPs, Matrix Metallopeptidases*.

###### 

**RTqPCR differential expression analysis results using samples from the validation cohort of microbial keratitis patients**.

  **Category**              **Gene**     **BK vs. C**   **FK vs. C**   **BK vs. FK**                     
  ------------------------- ------------ -------------- -------------- --------------- ---------- ------ -------
  **Immune response**       *CXCL5*      2792.89        3.21E-16       1564.99         9.69E-21   1.78   0.947
                            *CXCL6*      205.85         7.50E-06       196.07          3.68E-08   1.05   0.957
                            *CCL20*      1320.91        3.78E-16       656.98          8.32E-20   2.01   0.947
                            *CCL3L1*     147.23         1.95E-07       180.04          2.92E-11   0.82   0.947
                            *CXCL1*      109.8          2.93E-11       84.25           8.61E-15   1.3    0.947
                            *CXCL8*      1035.87        2.15E-14       1272.22         2.15E-21   0.81   0.947
                            *IL1B*       959.19         1.44E-13       1296.59         1.32E-20   0.74   0.947
                            *TNF*        65.29          1.98E-06       74.92           1.36E-09   0.87   0.947
                            *IL17A*      201.64         1.18E-04       218.43          1.27E-06   0.92   0.957
                            *IL23A*      1238.8         3.84E-14       1665.71         2.15E-21   0.74   0.947
                            *IFNG*       138.09         8.47E-04       129.84          4.11E-05   1.06   0.957
                            *IL18*       27.5           2.84E-05       19.34           2.76E-06   1.42   0.947
                            *IL12B*      190.28         3.71E-05       182.04          3.73E-07   1.05   0.957
                            *TREM1*      206.05         8.59E-10       423.63          4.60E-17   0.49   0.947
                            *CYTL1*      0.05           6.46E-03       0.03            1.32E-04   1.46   0.947
                            *AQP9*       1167.59        1.29E-13       1591.01         9.69E-21   0.73   0.947
  PRRs                      *CLEC4A*     135.1          1.03E-09       311.48          1.20E-17   0.43   0.947
                            *CLEC7A*     19.42          1.26E-04       24.77           3.23E-07   0.78   0.947
                            *FCER1G*     77.22          4.24E-09       145.47          4.32E-16   0.53   0.947
                            *FCN1*       268.45         5.35E-10       465.36          1.40E-16   0.58   0.947
                            *FPR1*       161.68         1.22E-10       253.77          2.15E-17   0.64   0.947
                            *SCARA3*     1.64           6.16E-01       0.93            9.28E-01   1.76   0.947
                            *TLR2*       270.16         1.68E-12       497.91          9.69E-21   0.54   0.947
                            *TLR4*       76.09          7.50E-06       106.71          2.72E-09   0.71   0.947
                            *MARCO*      398.21         1.38E-11       251.09          9.53E-15   1.59   0.947
                            *NLRP3*      35.68          3.72E-05       48.95           3.22E-08   0.73   0.947
  ECM                       *COL1A1*     6.66           2.91E-02       3.21            9.56E-02   2.07   0.947
                            *COL5A1*     61.06          5.24E-05       47.83           2.20E-06   1.28   0.947
                            *KERA*       0.03           1.28E-02       0.04            3.57E-03   0.8    0.947
                            *KRT6B*      2101.97        6.00E-21       2937.8          3.19E-31   0.72   0.947
                            *ALDH1A1*    1.8            5.27E-01       0.74            6.80E-01   2.44   0.947
  MMPs                      *MMP1*       536.49         1.39E-12       565.54          3.04E-18   0.95   0.957
                            *MMP10*      459.9          2.93E-11       405.57          1.17E-15   1.13   0.947
                            *MMP12*      2791.89        1.07E-08       717.96          3.14E-09   3.89   0.947
                            *MMP28*      12.71          1.70E-02       8.39            1.28E-02   1.52   0.947
                            *MMP7*       335.79         7.50E-09       296.06          3.26E-12   1.13   0.947
                            *MMP9*       7754.12        5.23E-22       11661.09        8.82E-33   0.66   0.947
                            *ADAM19*     156.56         7.64E-08       284.19          2.46E-13   0.55   0.947
  Anti-microbial peptides   *PI3*        4787.64        6.43E-23       5666.71         8.82E-33   0.84   0.947
                            *S100A7*     7119.6         1.44E-13       3891.02         1.90E-17   1.83   0.947
                            *S100A9*     831.43         6.43E-23       921.41          8.82E-33   0.9    0.947
                            *DEFB4B*     1421.62        6.51E-14       1208.72         2.57E-19   1.18   0.947
  Peptidase inhibitors      *SERPINA1*   134.64         1.29E-10       311.83          2.57E-19   0.43   0.947
                            *TIMP1*      3.81           1.23E-02       4.4             5.26E-04   0.87   0.947
                            *TIMP3*      1.09           9.26E-01       0.59            4.97E-01   1.84   0.947

*BK, Bacterial Keratitis; FK, Fungal keratitis; C, Controls; PRRs, Pattern Recognition Receptors; ECM, Extra-Cellular Matrix; MMPs, Matrix Metallopeptidases*.

![**Scatter plots showing log~2~ fold changes for corneal ulcer tissue analyzed using microarray vs. RTqPCR for (A)** fungal keratitis and **(B)** bacterial keratitis vs. controls (Spearman\'s rho 0.9, *p* \< 0.0001 for both).](fcimb-07-00193-g0002){#F2}

Discussion {#s4}
==========

In this study, we examined the main genes and biological processes contributing to pathogenesis in human MK. Even though we studied late stage keratitis up to 15 days post-symptom onset, we found a prominence of innate immune pathways among the DEGs in both BK and FK. In the microarray experiment all of the participants with BK experienced corneal perforation. Their corneal gene expression profile reflected this with differential expression of many genes associated with tissue destruction. *MMP9* had the highest fold change among all DEGs for BK in particular but also FK. The high level of *MMP9* gene expression may be due its production by many cell types including corneal epithelial cells (to aid their migration to close the wound), activated keratocytes, infiltrating macrophages and neutrophils, although the latter appear to be the main source (Matsubara et al., [@B30]; Wong et al., [@B52]; Mulholland et al., [@B34]; McClellan et al., [@B31]; Lin et al., [@B28]). MMP9 in addition to destroying Type IV collagen (the main collagen in DM) is able to cleave and activate pro-IL1B, thereby contributing to inflammation in the cornea (McClellan et al., [@B31]). Other MMPs also had highly upregulated gene expression in both BK and FK, including MMP10, blockade of which improves corneal epithelial healing in diabetic corneas (Saghizadeh et al., [@B38]). Pharmacological inhibition of MMPs with tetracyclines has shown some success toward halting corneal perforation in both animal models and human MK, and thus may prove to be a potential therapeutic target (Levy and Katz, [@B27]; McElvanney, [@B32]).

Laying down of new collagen to rebuild DM did not appear to occur effectively in BK, since the genes for key collagen subunits in DM (collagen type 8) were downregulated (Matsubara et al., [@B30]; Hopfer et al., [@B19]; McClellan et al., [@B31]; Dyrlund et al., [@B10]). BK tissue compared to FK had a higher proportion of type III collagen gene expression vs. type I, as well as versican, both of which contribute to a weaker wound that is more likely to perforate as explored previously in other tissues but not the cornea (Venkatesan et al., [@B48]; Eriksen et al., [@B12]; Andersson-Sjoland et al., [@B1]). Other factors contributing to weakness of the posterior-most layer of the cornea in BK were downregulation of gene expression of *claudin 5*, a major component of tight junctions between corneal endothelial cells, and *fibulin 2*, that gives elasticity and strength to DM (Nakasaki et al., [@B35]).

Evidence of corneal epithelial wound healing was present FK more than BK, with increased expression of genes in the cornified envelope protein category. Many genes that are part of the "epithelial differentiation complex" described in epidermal wound healing were found to be upregulated in both BK and FK. Genes such as *PI3, SLPI, S100A7* that are part of this complex also have antimicrobial activity. The broad-spectrum antimicrobial activity of PI3 and SLPI proteins have led to investigation into their potential as treatments for infectious diseases, and could therefore be explored as adjunct antimicrobials for keratitis (Williams et al., [@B51]).

Within the stroma, corneal keratocytes take on a characteristic expression profile toward a fibroblastic phenotype during healing (Hassell and Birk, [@B18]). We also observed this in both BK and FK with downregulation of *KERA, TKT, ALDH3A1*, and *ALDH1A1* genes, and upregulation of wound-healing collagen genes (*COL1A1, COL3A1*). Activated keratocytes differentiate into myofibroblasts upon exposure to growth factors such as TGFB, allowing them to express alpha smooth muscle actin and promote wound closure (Hassell and Birk, [@B18]). We found downregulation of the *TGFBR3* gene in both BK and FK and we did not detect the gene for the myofibroblast marker alpha-smooth muscle actin among the DEGs in BK or FK. The presence of highly upregulated *IL1B* gene in both BK and FK may have played a role in inhibiting the differentiation of fibroblasts to myofibroblasts (Mia et al., [@B33]).

Upregulation of specific PRRs genes gives an insight into the balance between pro- and anti-inflammatory pathways triggered in BK and FK. The *TLR4* gene was upregulated in BK, as previously reported in corneal scrapings from human BK (Karthikeyan et al., [@B23], [@B24]). However, activation of TLRs may not always bring about a pro-inflammatory response. Chronic TLR4 activation in bacterial infection with persistent lipopolysaccharide produces anti-inflammatory IL10, and in *Aspergillus* sp. infection results in reduced IL1B and IL6 production (Chai et al., [@B8]; Gurung et al., [@B17]). Further research is required into this tolerance effect and anti-inflammatory activity of TLRs that may contribute to persistence of pathogen in late stage keratitis.

Although innate immune response genes dominated the BK and FK transcriptome, there were also some DEGs that represented adaptive immune pathways, albeit with lower levels of differential expression. The T-cell associated IL7 receptor gene (*IL7R*) was more highly upregulated in BK samples than in FK. We did not directly detect differential expression of *IL17A-E*, in both BK and FK in the microarray cohort, but we did observe a much higher lever of *IL17A* gene expression in early stage FK samples compared to end-stage FK tissue in the microarray cohort, implying a role for this cytokine in the host response early on in fungal keratitis. Also, in BK, the early stage ulcers had higher expression of the *IL23A* and *IL12B* genes, which together encode the components of the IL23 cytokine, that can maintain Th17 cells. In addition, the *IFNG* gene was also expressed more highly in early stage FK rather than late stage FK tissue. Karthikeyan et al. also found the *IFNG* gene to be differentially expressed in both early and late stage ulcers in human FK, and correlated this to the presence of CD3+ and CD4+ cells in the immunohistochemical analysis of late stage ulcers, implying a Th1 response (Karthikeyan et al., [@B23]). Further studies are required to more fully explore the balance of Th1 and Th17 responses in early vs. late stages of human MK.

The gene expression profile of BK compared to control tissue showed a much greater degree of differential expression than in FK, with higher fold changes in pro-inflammatory genes. *CXCL2* gene had the highest fold change in BK among the chemokines and this gene promotes persistent neutrophil influx even in later stages of keratitis (Kernacki et al., [@B25]).

The most prominent gene signature in the BK tissue was the upregulation of the transcription factor *HIF1A* and many of its induced genes. The presence of *HIF1A* appears to be essential for successful resolution of BK in Pseudomonal infection, as siRNA or pharmacological blockade results in less NO production, ineffective bacterial killing and ultimately corneal perforation in a murine model of disease (Berger et al., [@B4]). It acts as a transcription factor to increase the expression of multiple genes required for the clearance of infection, and as such has been described as a master regulator of innate immunity; *HIF1A* has a preferential effect on promoting activity of neutrophils and macrophages, boosting their antimicrobial activities through sustained glycolysis in hypoxic conditions. This occurs mainly through upregulation of mitochondrial genes, which we also detected in our BK samples. However, *HIF1A* has the opposite effect on T-cells and so may suppress the adaptive immune response (Bhandari and Nizet, [@B5]). Augmentation of the activity of *HIF1A* or molecules within its pathway early on in the disease process have been explored as a therapeutic option for some infections, but is yet to be investigated in MK (Bhandari and Nizet, [@B5]).

Both types of network analyses used in this study (PPI and network co-expression analyses) complemented the findings of the differential expression analyses, with the most highly interconnected gene clusters being enriched for immune response GO terms, including aspects of the innate immune response (such as macrophage activity in BK, or TLR4 activity and chemokine production in both BK and FK) as well as the adaptive system (such as transcription factor for Th17 cell differentiation in BK, and regulation of T-cell activation in both BK and FK in the network co-expression analyses). Multiple genes associated with actin filament reorganization were found to be highly interconnected in BK; this may be due to the fact that dynamic actin filament changes are required for many cellular antibacterial functions, such as cell migration and phagocytosis (both of which were in the list of enriched GO terms for DEGs common to BK and FK).

In this study, we used control tissue from donors who were significantly older than the keratitis patients, as tissue from younger donors was prioritized for use in corneal transplantation. Although this may have resulted in reduced cell density, particularly keratocytes and endothelial cells, due to the effect of age (Patel et al., [@B36]; Sanchis-Gimeno et al., [@B39]), we believe that the marked differences in gene expression observed between cases and controls are more likely to be driven by the presence of infection, rather than a moderate difference in age. Another limitation of this study is that we have focused on the host but not the pathogen transcriptome. Keratitis-causing pathogens can also contribute to disease pathogenesis through evasion of host immune mechanisms, promotion of host cell apoptosis and production of ECM-destroying enzymes (Burns et al., [@B6]; Gopinathan et al., [@B14]). Further studies are needed to more fully explore the host-pathogen interaction in MK. We found a great deal of similarity in the transcriptome between bacterial and fungal samples as demonstrated in the global gene expression profiles. Previous studies have also found an overlap in human gene expression responses from late stage *Aspergillus* and *Fusarium* keratitis as well as *S. pneumoniae* vs. *P. aeruginosa* keratitis (Karthikeyan et al., [@B23], [@B24]). Future studies with a larger sample size may be able to more fully elucidate the time point at which the transcriptomic response to these infections in the cornea begin to converge.

In summary, we have reported the human transcriptional response of late stage corneal ulcer tissue following bacterial and fungal infection in the human cornea, and have focused on many genes that have not been previously explored in keratitis. Our findings provide an initial foundation for further exploration of some of these genes as potential prognostic biomarkers or therapeutic targets to treat this blinding eye disease.
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**Hierarchical Clustering dendrogram (A)** and Principal Components Analysis plot **(B)** for the raw data for all samples (i.e., all expressed probes prior to normalization) which clearly show that M80, M50, and M73 (shown with an asterix in the PCA plot) cluster away from all other samples in these plots.
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**Network maps of the Protein-Protein Interaction Analysis for Bacterial Keratitis vs. Control and Fungal Keratitis vs. Control, as well as the network co-expression analysis for all differentially expressed genes in bacterial and fungal keratitis**.
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**Details of primers used for RTqPCR TLDA Experiment (Life Technologies, USA)**.
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**Demographic, Clinical, and Microbiological Data for All Microarray Participants**.
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###### 

**List of differentially expressed genes, fold changes, and false-discovery rate (FDR) adjusted *p*-values in the three microarray pairwise comparisons (FK vs. C, BK vs. C, and BK vs. FK)**.
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###### 

**Gene ontology enrichment analysis for the differentially expressed genes common to both bacterial and fungal keratitis: biological process (BP_FAT), molecular function (MF_FAT), and cellular component (CC_FAT) terms from DAVID v6.8**.

###### 

Click here for additional data file.

###### 

**Gene ontology term enrichment analysis for each of the seven most highly connected gene clusters in the network co-expression analysis (using DAVID v6.8)**. Normalized expression intensities of all differentially expressed genes in the bacterial and fungal keratitis vs. control comparisons used to create network graph in Miru).

###### 

Click here for additional data file.

###### 

**Comparison of early stage samples from the validation cohort (symptom duration ≤7 days) with microarray tissue samples**.

###### 

Click here for additional data file.
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